The potential to regress or normalize left ventricular hypertrophy (LVH) depends entirely on the underlying pathophysiology. While true “normalization” is challenging in advanced stages, significant reverse remodeling and reduction in LV mass index are frequently achievable with targeted pharmacotherapy.
Here is a breakdown of regression potential based on the primary etiology:
| Etiology | Potential for Regression | Primary Mechanism/Agent |
| Hypertensive LVH | High | RAAS inhibition, afterload reduction |
| Hypertrophic Cardiomyopathy | Moderate to High (Emerging) | Cardiac myosin inhibition (Mavacamten) |
| Infiltrative (Amyloidosis) | Low to Moderate | Disease-modifying agents (Tafamidis, chemotherapy) |
| Storage (Fabry Disease) | Moderate (if early) | Enzyme replacement therapy (ERT) |
| Aortic Stenosis | High (Post-intervention) | Valve replacement (TAVR/SAVR) |
Hypertensive Heart Disease
In pressure-overload LVH driven by systemic hypertension, medical therapy is highly effective at inducing reverse remodeling. The degree of regression is not solely dependent on the magnitude of blood pressure reduction, but also on the specific drug class utilized.
- RAAS Inhibitors: ACE inhibitors and ARBs are the most effective agents for LVH regression. They directly counter the trophic effects of Angiotensin II on the myocardium, reducing both myocyte hypertrophy and interstitial fibrosis.
- Calcium Channel Blockers (CCBs): Non-dihydropyridines and long-acting dihydropyridines (like amlodipine) also demonstrate significant efficacy in reducing LV mass.
- Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone and eplerenone are particularly valuable for mitigating myocardial fibrosis associated with elevated aldosterone levels.
- Note: Beta-blockers (except vasodilatory ones like carvedilol or nebivolol) and pure vasodilators (like hydralazine) are generally less effective for LV mass regression despite adequate blood pressure control.
Hypertrophic Cardiomyopathy (HCM)
Historically, medical therapy for HCM (beta-blockers, non-dihydropyridine CCBs, disopyramide) focused exclusively on symptom management and reducing left ventricular outflow tract (LVOT) gradients, without altering the underlying disease progression or inducing reverse remodeling.
This paradigm has shifted with the introduction of cardiac myosin inhibitors.
- Mavacamten: By reducing the excessive number of actin-myosin cross-bridges, mavacamten directly targets the underlying pathophysiology of obstructive HCM. Clinical trials (EXPLORER-HCM and VALOR-HCM) have demonstrated not only significant reductions in LVOT gradients but also favorable cardiac remodeling, including measurable reductions in LV mass index and left atrial volume.
Infiltrative and Storage Diseases
Thickened myocardium in these conditions is not true cellular hypertrophy but rather the extracellular or intracellular accumulation of abnormal substrates.
- Cardiac Amyloidosis: In ATTR amyloidosis, tafamidis stabilizes the transthyretin tetramer, slowing the deposition of amyloid fibrils. While it significantly reduces mortality and cardiovascular hospitalizations, it primarily halts disease progression rather than reversing established myocardial thickening. In AL amyloidosis, successful chemotherapy or autologous stem cell transplant (ASCT) can eventually lead to a gradual reduction in wall thickness over time, though this is a slow process.
- Fabry Disease: Intracellular accumulation of globotriaosylceramide can mimic HCM. Enzyme replacement therapy (ERT) or chaperone therapy (migalastat) can halt progression and, if initiated early before extensive fibrosis occurs, can result in a reduction of LV mass.